The title specifies evaluation of the influenza vaccine among school-aged children during the 2024–2025 season in Shenzhen, China. The JINA-provided PubMed content identifies the study population and season, but the source did not include the abstract text or participant-level details. Investigators are affiliated with the Shenzhen Center for Disease Control and Prevention, Sun Yat-sen University (Shenzhen), the University of Hong Kong, Shenzhen Children’s Hospital and other local institutions. These affiliations suggest the work was regionally organized and clinically oriented toward pediatric and public-health practice.
The PubMed record lists the geographic and temporal scope clearly in the title, yet it does not report age strata, enrollment sites (for example, primary versus secondary schools), or baseline vaccination coverage among the cohort. The absence of those details in the provided content limits immediate interpretation for school-based vaccination planning or outbreak response.
The authors labeled the investigation a test-negative design in the article title. That design typically compares odds of vaccination among patients who test positive for influenza with odds among test-negative controls who present with similar illness; it is commonly used to estimate vaccine effectiveness in outpatient and sentinel surveillance settings. The PubMed snippet, however, did not include methods or diagnostic details—so the source did not report laboratory assays used, case definitions for acute respiratory illness, or the time windows for specimen collection relative to symptom onset.
Because the JINA text lacks methodological specifics, the following were not available from the source: selection criteria for cases and controls, any adjustment variables (age, comorbidity, prior vaccination), and analytic approach (logistic regression or other modelling). Those items are necessary to judge bias risk in test-negative analyses, and they remain unspecified in the provided record.
The manuscript is authored by Jianhua Lu and a multidisciplinary team; the PubMed entry lists multiple co-authors and nine institutional affiliations, including Shenzhen CDC and academic public-health departments. Publication metadata present in the source: Vaccine. 2026 Oct 24:92:129100. DOI 10.1016/j.vaccine.2026.129100. The article was available online (Epub) on 6 September 2026 and is indexed under PMID 42702143.
This level of bibliographic detail allows clinicians to locate the full text. The JINA content included no conflict-of-interest statement text nor the abstract content; readers should consult the publisher or full-text link for protocol and results.
The PubMed content provided by JINA did not contain the study abstract or outcome data. The source did not report any vaccine effectiveness estimates, confidence intervals, subgroup analyses, or safety outcomes. Sample size and the number of laboratory-confirmed influenza cases were not included. The vaccine type(s) administered (e.g., inactivated, live-attenuated, quadrivalent vs trivalent) were also not specified in the available record.
Because those results are missing from the source text supplied here, this rewrite does not infer effectiveness values or clinical impacts. Readers and clinicians requiring effect estimates, methodologic detail, or season-specific antigen match information must consult the article full text through Vaccine or the PubMed full-text links.
The PubMed snapshot leaves several operational and clinical questions unanswered in the supplied content: what magnitude of protection did investigators report for the 2024–25 season; how did effectiveness vary by age band within school-aged children; whether the vaccine was well matched to circulating strains; and which laboratory assay confirmed influenza infection. The source did not present these outcomes.
Clinicians and public-health teams interested in school immunization policy, outbreak control, or seasonal vaccine recommendations should retrieve the full article for effect estimates, adjusted analyses, and any statements about vaccine performance against influenza A versus B. The PubMed entry provides the DOI and PMID for retrieval, but the abstract and numeric results are not reproduced in the JINA content.
Limitations noted in the source content
The only limitations that can be documented from the provided record are metadata-level: absent abstract and missing methods/results in the JINA excerpt. The study’s internal limitations—such as selection bias, misclassification, residual confounding, or sample-size constraints—were not available in the PubMed text supplied here.
Next steps to obtain full clinical detail
To evaluate clinical applicability, obtain the full text via the Vaccine journal link (DOI 10.1016/j.vaccine.2026.129100) or institutional access. The full article should report vaccine effectiveness estimates, analytic methods, laboratory confirmation criteria, and any subgroup analyses relevant to pediatric practice and school-based interventions. This rewrite stops at concrete, source-documented metadata and identifies the precise missing elements clinicians need to assess real-world vaccine performance.